{"id":"W4379328967","doi":"10.1200/jco.2023.41.16_suppl.tps1115","title":"HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Internal medicine; Metastatic breast cancer; Capecitabine; Oncology; Trastuzumab; Neratinib; Taxane; Progression-free survival; Breast cancer; Cancer; Colorectal cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002353773,0.0001963594,0.001733641,0.0002419019,0.00004164372,0.000007132963,0.0001476245,0.0001195734,0.00008009696],"category_scores_gemma":[0.001017519,0.0001172863,0.0001455047,0.0004439309,0.000257642,0.000166624,0.00002229003,0.0005365252,0.000001195716],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002855567,"about_ca_system_score_gemma":0.002059181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001174241,"about_ca_topic_score_gemma":0.0005031635,"domain_scores_codex":[0.9968424,0.0003763659,0.001846078,0.0002655043,0.0003793102,0.0002902955],"domain_scores_gemma":[0.9941221,0.003226519,0.001637346,0.0001730808,0.0006315704,0.0002094054],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.232406,0.015388,0.02147126,0.0001280623,0.001007488,0.0006153982,0.00298747,0.0001427477,0.0002086989,0.00005072334,0.0004035798,0.7251905],"study_design_scores_gemma":[0.3421533,0.2609029,0.3613512,0.0007360444,0.0005586186,0.002606437,0.02046424,0.00093293,0.00009983593,0.0009749238,0.008947102,0.0002724995],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880046,0.0003269952,0.0002395504,0.009618373,0.0003530867,0.001378028,0.00002491787,0.00001456646,0.0000398917],"genre_scores_gemma":[0.995699,0.001135269,0.001660445,0.0008230567,0.0002078155,0.0001261108,0.000003388109,0.00003861251,0.0003063179],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.724918,"threshold_uncertainty_score":0.4782799,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1344986167028801,"score_gpt":0.5150052673203316,"score_spread":0.3805066506174515,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}